Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618592 | 1.00 | SLC5A2 (0.49) | SLC5A2SLC5A1TYRACHECA12 | |
| SCHEMBL13098422 | 0.92 | SLC5A2 (0.41) | SLC5A2SLC5A1TYRCA12CA9 | |
| SCHEMBL13088373 | 0.92 | SLC5A2 (0.41) | SLC5A2SLC5A1TYRCA12CA9 | |
| SCHEMBL13254718 | 0.86 | SLC5A2 (0.50) | SLC5A2SLC5A1TYRACHECA12 | |
| Atigliflozin SCHEMBL14981898 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1TYRACHE | |
| Atigliflozin SCHEMBL19276485 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1TYRACHE | |
| Atigliflozin SCHEMBL873867 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1TYRACHE | |
| Atigliflozin SCHEMBL874745 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1TYRACHE | |
| Atigliflozin SCHEMBL13641405 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1TYRACHE | |
| Atigliflozin SCHEMBL13644156 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1TYRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, PPARG | SLC5A2 1/4885SLC5A1 2/4885TYR 4775/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885TYR 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.